Annual report pursuant to Section 13 and 15(d)

Note 16 - Segments - Segment Information (Details)

v3.21.1
Note 16 - Segments - Segment Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenue from contract with customer $ 119,000 $ 38,000
Grant and other revenue 796,288 631,208
Revenues, Total 915,013 657,826
Cost of revenue 1,048 6,667
Research and Development Expense, Total 4,930,187 5,338,267
Selling, general and administrative expenses, excluding depreciation and amortization [1] 6,624,566 6,130,897
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 70,393 144,512
Loss from operations [3] (10,711,181) (10,962,517)
Other expense [4] (10,510) 17,675
Net loss (10,721,691) (10,948,214)
Total assets, net of depreciation and amortization 7,758,018 4,150,906
Capital expenditures 135,881 1,258
Provision for income taxes (707)
Loss from continuing operations   (10,945,549)
Loss from discontinued operations, net of tax effect   (2,665)
UNITED STATES    
Total assets, net of depreciation and amortization 7,555,227 4,150,906
Non-US [Member]    
Total assets, net of depreciation and amortization 202,791
Royalty [Member]    
Revenue from contract with customer 7,995 16,665
License [Member]    
Revenue from contract with customer 110,730 9,953
Diagnostics Segment [Member]    
Grant and other revenue 482,221 384,776
Revenues, Total 600,946 411,394
Cost of revenue 1,048 6,667
Research and Development Expense, Total 4,593,459 4,795,445
Selling, general and administrative expenses, excluding depreciation and amortization [1] 299,959
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 10,068
Loss from operations [3] (4,303,588) (4,390,718)
Other expense [4]
Net loss (4,303,588) (4,393,666)
Capital expenditures 120,810
Provision for income taxes   (284)
Loss from continuing operations   (4,391,002)
Loss from discontinued operations, net of tax effect   (2,665)
Diagnostics Segment [Member] | UNITED STATES    
Total assets, net of depreciation and amortization 139,121 55,229
Diagnostics Segment [Member] | Non-US [Member]    
Total assets, net of depreciation and amortization 202,791
Diagnostics Segment [Member] | Royalty [Member]    
Revenue from contract with customer 7,995 16,665
Diagnostics Segment [Member] | License [Member]    
Revenue from contract with customer 110,730 9,953
Therapeutics Segment [Member]    
Grant and other revenue 314,067 246,432
Revenues, Total 314,067 246,432
Cost of revenue
Research and Development Expense, Total 336,728 542,822
Selling, general and administrative expenses, excluding depreciation and amortization [1] 800 16,990
Depreciation, Depletion and Amortization, Nonproduction, Total [2]
Loss from operations [3] (23,461) (313,380)
Other expense [4]
Net loss (23,461) (313,400)
Capital expenditures
Provision for income taxes   (20)
Loss from continuing operations   (313,400)
Loss from discontinued operations, net of tax effect  
Therapeutics Segment [Member] | UNITED STATES    
Total assets, net of depreciation and amortization 31,449
Therapeutics Segment [Member] | Non-US [Member]    
Total assets, net of depreciation and amortization
Therapeutics Segment [Member] | Royalty [Member]    
Revenue from contract with customer
Therapeutics Segment [Member] | License [Member]    
Revenue from contract with customer
Corporate Segment [Member]    
Grant and other revenue
Revenues, Total
Cost of revenue
Research and Development Expense, Total
Selling, general and administrative expenses, excluding depreciation and amortization [1] 6,323,807 6,113,907
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 60,325 144,512
Loss from operations [3] (6,384,132) (6,258,419)
Other expense [4] (10,510) 17,675
Net loss (6,394,642) (6,241,147)
Capital expenditures 15,071 1,258
Provision for income taxes   (403)
Loss from continuing operations   (6,241,147)
Loss from discontinued operations, net of tax effect  
Corporate Segment [Member] | UNITED STATES    
Total assets, net of depreciation and amortization 7,416,106 4,064,228
Corporate Segment [Member] | Non-US [Member]    
Total assets, net of depreciation and amortization
Corporate Segment [Member] | Royalty [Member]    
Revenue from contract with customer
Corporate Segment [Member] | License [Member]    
Revenue from contract with customer
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2] Depreciation and amortization are reflected in selling, general and administrative expenses ($70,393 and $144,512 for the years ended December 31, 2020 and 2019, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[4] Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.